TherapeuticsMD, Inc.: Form 10-Q for the period ended Jun 30, 2012
Filed with the SEC on Aug 9, 2012 and accepted by EDGAR at Aug 9, 2012, 17:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-04-01 to 2012-06-30 | $819.1k | us-gaap:SalesRevenueNet |
| Revenue | 6 months2012-01-01 to 2012-06-30 | $1.5m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2012-04-01 to 2012-06-30 | $372.4k | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2012-01-01 to 2012-06-30 | $708.5k | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2012-04-01 to 2012-06-30 | $446.8k | us-gaap:GrossProfit |
| Gross profit | 6 months2012-01-01 to 2012-06-30 | $832.3k | us-gaap:GrossProfit |
| Research and development | 3 months2012-04-01 to 2012-06-30 | $833.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2012-01-01 to 2012-06-30 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2012-04-01 to 2012-06-30 | $3.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2012-01-01 to 2012-06-30 | $6.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2012-04-01 to 2012-06-30 | −$4.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2012-01-01 to 2012-06-30 | −$6.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-04-01 to 2012-06-30 | $92.8k | us-gaap:InterestExpense |
| Interest expense | 6 months2012-01-01 to 2012-06-30 | $141.5k | us-gaap:InterestExpense |
| Net income | 3 months2012-04-01 to 2012-06-30 | −$11.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2012-01-01 to 2012-06-30 | −$25.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-04-01 to 2012-06-30 | −$0.14 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2012-01-01 to 2012-06-30 | −$0.29 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2012-01-01 to 2012-06-30 | −$5.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2012-01-01 to 2012-06-30 | $66.4k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-06-30 | $1.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-06-30 | $3.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2012-06-30 | $4.9m | us-gaap:Assets |
| Current liabilities | At period end2012-06-30 | $2.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-06-30 | $5.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-06-30 | −$704.4k | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2012-06-30 | 95,750,212 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001387131-12-002558. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.